|
rs28934575
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
rs2073664
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Adenocarcinoma (ADCC) patients carrying the heterozygous (CT) genotype for DKK4 rs2073664 showed a better OS compared with wild genotype (log rank p = 0.01).
|
30346805 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.
|
29248665 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.
|
29248665 |
2018 |
|
rs577715207
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A commercially available monoclonal antibody against S100P</span> stained 78% of 300 urothelial carcinomas while only 2% of 256 prostatic adenocarcinomas</span> and none of 137 renal cell carcinomas stained.
|
17460449 |
2007 |
|
rs577715207
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A common set of genes dysregulated in lung cancer was obtained, including BPA1, DUSP6, ASCL1, RNAS1 and S100P. p63 and CK 5/6 p63 are useful for differentiating adenocarcinoma and small cell lung cancer from squamous cell carcinoma.
|
20332665 |
2010 |
|
rs1454328441
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A common set of genes dysregulated in lung cancer was obtained, including BPA1, DUSP6, ASCL1, RNAS1 and S100P. p63 and CK 5/6 p63 are useful for differentiating adenocarcinoma and small cell lung cancer from squamous cell carcinoma.
|
20332665 |
2010 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A gefitinib-resistant point mutation (T790M) in exon 20 without gefitinib treatment was detected in 1 AAH and 1 adenocarcinoma.
|
17561305 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20.
|
17618013 |
2007 |
|
rs143752852
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A mutation (T915C: L296P) was found in an adenocarcinoma specimen.
|
10959094 |
2000 |
|
rs3136038
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant association to decreased risk of lung cancer was observed in major allele C of rs3136038 carriers (adjusted OR=0.57, 95% CI=0.39-0.84 for CT; adjusted OR=0.75, 95% CI=0.52-1.10 for CC; adjusted OR=0.68, 95% CI=0.46-0.99 for CT+CC, compared with genotype TT), and additionally, referenced with homozygote TT, the heterozygous genotype CT showed a distinct protective effect in younger subjects (adjusted OR=0.47, 95% CI=0.26-0.86), in males (adjusted OR=0.59, 95% CI=0.37-0.93), in non-smokers (adjusted OR=0.38, 95% CI=0.20-0.72), in subjects without family history of cancer (adjusted OR=0.52, 95% CI=0.34-0.80) and in adenocarcinomas patients (adjusted OR=0.51, 95% CI=0.31-0.84).
|
18068852 |
2008 |
|
rs10937405
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A statistically significant association between adenocarcinoma risk and SNP genotype was shown: rs10937405, OR = 1.21, P = 1.82 × 10(-4); rs17429138, OR = 1.23, P = 7.49 × 10(-5); and rs4396880, OR = 1.21, P = 2.03 × 10(-4).
|
21610222 |
2011 |